Literature DB >> 18368377

[Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].

M J Behne1, U Hauswirth, A Menz, N Brüllke, U Müllerleile, I Moll.   

Abstract

For some time now, there have been reports of acral necrosis as a paraneoplasia that may occur in association with a number of different malignant tumours. There have also been a series of reports about acral necrosis associated with chemotherapy with various cytostatics. The treatment of choice if these lesions occur is plasmapheresis. Ultimately, the occurrence of thrombotic microangiopathy (TMA) can only be prevented by close monitoring through regular laboratory controls before each new cycle of chemotherapy. In the differential diagnosis, Raynaud's syndrome should be considered as a premonitory paraneoplasia, a risk factor for the occurrence of acral necrosis in patients with a malignant tumour undergoing chemotherapy, particularly patients with ovarian carcinoma receiving gemcitabine treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18368377     DOI: 10.1007/s00105-008-1494-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  47 in total

1.  [Is the frequency of hemolytic uremic syndrome as a complication of gemcitabine underestimated? The role of systematic screening].

Authors:  Jérôme Desramé; Christian Duvic; Dominique Béchade; Christian Bredin; J J Raynaud; G Defuentes; Louis-Marie Dourthe; Jean-Pierre Algayres
Journal:  Gastroenterol Clin Biol       Date:  2006-02

Review 2.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

3.  Longitudinal study of patients with anticentromere antibody.

Authors:  K Takehara; Y Soma; A Igarashi; K Kikuchi; T Tamaki; Y Ishibashi
Journal:  Dermatologica       Date:  1990

4.  Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.

Authors:  D D Gerbracht; V D Steen; G L Ziegler; T A Medsger; G P Rodnan
Journal:  Arthritis Rheum       Date:  1985-01

5.  Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen.

Authors:  Y Asada; A Sumiyoshi; T Hayashi; J Suzumiya; K Kaketani
Journal:  Thromb Res       Date:  1985-06-01       Impact factor: 3.944

6.  Association between digital ischaemia and malignant disease.

Authors:  P R Hawley; A W Johnston; J T Rankin
Journal:  Br Med J       Date:  1967-07-22

7.  Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura.

Authors:  T W Chow; N A Turner; M Chintagumpala; P D McPherson; L H Nolasco; L Rice; J D Hellums; J L Moake
Journal:  Am J Hematol       Date:  1998-04       Impact factor: 10.047

8.  [Antinuclear antibodies (ANA) in patients with malignant diseases: frequency of occurrence and immunological characterization (author's transl)].

Authors:  H Idel; R Bunke; N Seemayer
Journal:  Zentralbl Bakteriol B       Date:  1978-09

Review 9.  Gemcitabine as a single-agent treatment for ovarian cancer.

Authors:  Wesley C Fowler; Linda Van Le
Journal:  Gynecol Oncol       Date:  2003-08       Impact factor: 5.482

10.  A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.

Authors:  Basil F El-Rayes; Mark Zalupski; Anthony F Shields; Stephanie G Manza; Patricia LoRusso; Philip A Philip
Journal:  Am J Clin Oncol       Date:  2007-04       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.